Roche Glycart
Schlieren
About Roche Glycart
Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $13.6M
- Funding stage: M&A
- Last round: Series A (Nov 2003)
- Website: roche.chschlieren.html
- Phone: +41447556161
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/roche-glycart-2712853 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.